Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Aprocitentan (Primary)
- Indications Resistant hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PRECISION
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 20 Jun 2018 The study will be conducted in approximately 100 sites in around 20 countries, according to an Idorsia media release.
- 20 Jun 2018 Status changed from not yet recruiting to recruiting, as reported in the Idorsia media release.
- 30 May 2018 Status changed from planning to not yet recruiting.